Zota Health Care logo

Zota Health Care financials and balance sheet

NSE: ZOTAPharmaceuticals & BiotechnologySmall Cap

Last close ₹1,242.70down ₹30.40 (2.39%)

Share price at the NSE close on 23 Oct 2026. Previous close ₹1,273.10.

52-week range of traded prices to 23 Oct 2026
₹1,022.00Low, 2 Sep 2026₹1,740.00High, 21 Nov 2025
Market cap
₹4,304 Cr838th largest listed
P/E
Lossover the last 12 months
P/B
6.2
Dividend yield
0.08%
ROE
−22.5%
ROCE
−12.8%
Debt to equity
0.04
Volume, NSE
73,93258.6% delivered

10 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Zota Health Care annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
Peak revenue ₹407 Cr, year to Mar 2026A loss in 1 of the 10 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue407
  2. Materials and goods−229
  3. Employee costs−49
  4. Other expenses−98
  5. Operating profit32
  6. Depreciation−4.0
  7. Other income+13
  8. One-off items−1.0
  9. Finance costs−0.3
  10. Profit before tax40
  11. Tax−12
  12. Net profit28

What the company owns

  • Plant, investments and other assets₹756 Cr
  • Receivables₹176 Cr
  • Inventory₹83 Cr
  • Cash and bank₹2 Cr

What pays for it: net worth and liabilities

  • Net worth₹888 Cr
  • Owed to suppliers₹76 Cr
  • Other liabilities₹30 Cr
  • Borrowings₹22 Cr

Profit and loss

Standalone, ₹ crore, years to March.Zota Health Care quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Filed 24 JunMar 2021Filed 26 JunMar 2022Filed 31 MayMar 2023Filed 31 MayMar 2024Filed 30 MayMar 2025Filed 29 MayMar 2026Filed 22 May
Revenue from operations72788695107132138167257407
62677891106116130160246375
Materials and goods bought45515766738888104155229
Employee costs6791091011203149
Other expenses1091214241931365998
Operating profit before depreciation101185115861132
Operating margin14.0%14.0%9.0%4.8%0.6%11.7%5.8%3.7%4.4%7.8%
Materials, % of revenue63.1%65.6%66.6%69.7%68.6%66.6%63.8%62.7%60.4%56.2%
Employee costs, % of revenue8.6%8.5%10.4%10.9%8.7%7.5%8.3%12.0%12.1%12.0%
Other expenses, % of revenue14.3%11.9%14.0%14.7%22.0%14.3%22.2%21.6%23.0%24.0%
Depreciation and amortisation1112332334
Operating profit after depreciation91062−21363828
Other income02221232513
Finance costs1000000010
Profit before one-off items and tax811–4−114851241
One-off items000010100−1
Profit before tax81184014951240
34210422312
Net profit676301173928
Other comprehensive income––00000000
Total comprehensive income––5301174928
Net margin7.7%9.3%6.5%2.9%−0.2%8.0%4.8%2.0%3.3%6.9%

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2023Filed 31 MayMar 2024Filed 30 MayMar 2025Filed 29 MayMar 2026Filed 22 May
94122317888
Share capital25262935
Reserves6996289854
Borrowings015022
295061125
Liabilities due after a year1122
Total assets1251733801,016
3744193716
88129186300
Net debt−115−120
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017, Mar 2018, Mar 2019, Mar 2020, Mar 2021 and Mar 2022, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Filed 26 JunMar 2022Filed 31 MayMar 2023Filed 31 MayMar 2024Filed 30 MayMar 2025Filed 29 MayMar 2026Filed 22 May
−114−10−30−22−46
019−6−27−15−22
−22−17−35−31−69
Receivables0−9−5−30−29−73
Inventories−30−8−4−19−24
Payables13761530
Other working capital08−11−73−3
Tax paid0−4−2−2−3−11
Interest paid000000
Capital spending1155421
Free cash flow−112−15−35−26−66
4−2713−9−148−515
−214−438171561
Dividends paid234333
Shares bought back000000
Shares issued017026189586
Net change in cash11−1−110
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.Zota Health Care dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Filed 24 JunMar 2021Filed 26 JunMar 2022Filed 31 MayMar 2023Filed 31 MayMar 2024Filed 30 MayMar 2025Filed 29 MayMar 2026Filed 22 May
––₹2.26₹1.12−₹0.07₹4.25₹2.62₹1.32₹3.16₹8.48
As stated that year––₹3.16₹1.12−₹0.07₹4.25₹2.62₹1.32₹3.16₹8.48
––₹2.26₹1.12−₹0.07₹4.25₹2.62₹1.29₹2.91₹8.48
₹1.43₹2.14₹1.00₹1.00₹1.00₹1.50₹1.00₹1.00₹1.00₹1.00
Book value per share––––––₹37.54₹47.11₹110.83₹256.46
Dividend payout––44.2%89.0%–35.7%38.2%76.5%33.2%12.4%
Shareholder yield––––0.7%−1.9%0.5%−1.9%−8.1%−16.2%
Market cap at the year end (₹ crore)––4563203407497091,2262,3063,596
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from.

Ratios

Standalone, years to March.Zota Health Care PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Filed 24 JunMar 2021Filed 26 JunMar 2022Filed 31 MayMar 2023Filed 31 MayMar 2024Filed 30 MayMar 2025Filed 29 MayMar 2026Filed 22 May
Revenue growth–8.8%10.0%11.1%12.3%23.1%5.2%20.4%54.4%58.2%
Operating profit growth–8.6%−28.9%−41.5%−85.1%2,171.6%−47.8%−22.3%83.9%175.7%
Net profit growth–31.2%−23.6%−50.3%––−37.7%−48.7%155.0%223.8%
Earnings per share growth–––−50.4%––−38.4%−49.6%139.4%168.4%
––––––7.0%3.1%3.9%4.6%
–––––––−3.9 pts0.8 pts0.7 pts
From the net margin–––––––−4.0 pts2.0 pts4.1 pts
From asset turnover–––––––0.0 pts−0.9 pts−3.0 pts
From borrowing–––––––0.1 pts−0.4 pts−0.4 pts
Return on capital employed––––––5.9%2.4%2.6%3.0%
Cash conversion–––––129.1%−156.1%−891.9%−257.8%−163.5%
Interest cover13.282.3172.635.3–172.488.38.87.8109.3
Debt to equity––––––0.000.120.000.02
Receivable days––––––115162146157
Inventory days––––––148140140133
Payable days––––––103108109122
Cash conversion cycle, days––––––160194177168
Working capital days––––––152204177175
Asset turnover––––––1.111.120.930.58
Assets per rupee of net worth––––––1.321.381.261.16
Sales per rupee of plant––––––19.3521.1530.4213.42
Capital spending to depreciation––––0.170.462.071.761.345.20
Plant being built, % of plant in use––––––43.3%60.9%65.9%0.0%
Interest cover is left blank for the year to Mar 2021: operating profit after depreciation is a loss, and a loss covers no interest bill. No balance sheet is on record for the years to Mar 2017, Mar 2018, Mar 2019, Mar 2020, Mar 2021 and Mar 2022, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
4.0%
Cash from operations against operating profit
−144.6%
Measure10 years5 years3 years
Revenue growth, yearly rate–30.7%43.3%
Profit growth, yearly rate––61.8%
Return on equity, average–4.7%3.9%
Return on capital employed, average–3.5%2.7%
Operating margin, average7.6%6.7%5.3%
Net margin, average5.1%5.0%4.1%
Asset turnover, average–0.940.88
Cash conversion cycle, days, average–175180
Interest cover, average76.777.342.0
Debt to equity, average–0.040.05

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations−95−98−46
Cash from investing−686−672−515
Cash from financing781771561
Capital spending363021
Dividends paid1583
Shares bought back000
Shares issued for cash818801586
Borrowings raised––22
Borrowings repaid000

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Effective tax ratePublished threshold 17.16 per cent33.7435.92––––––––
A threshold marked as ours has no published figure; it is the line we read the check against.